試す 金 - 無料
Omission of phytochemistry in UG Dravyaguna curriculum
Chronicle Pharmabiz
|November 13, 2025
PHYTOCHEMISTRY has been once an integral part of the undergraduate syllabus by Central Council of Indian Medicine.
Recently, Dravyaguna syllabus has been revised by the National Commission of Indian Medicine and surprisingly enough, phytochemistry has been omitted and number of the medicinal plants has been reduced considerably. This is the striking difference between the syllabus designed by CCIM and NCISM.
What is the connection between dravyaguna and phytochemistry? Dravyaguna is closely allied to botany, ethnobotany, pharmacognosy and pharmacology. Dravyaguna was not included in the eight branches coined for Ayurveda but was carved out as a separate subject. Dravyaguna is often categorized as non-clinical subject providing a basis to the clinical subjects.
Some experts are advocating an interdisciplinary nature of dravyaguna and ethnopharmacology. In fact, several articles published in journals related to integrative medicine have addressed ayurvedic medicine as reverse pharmacology and dravyaguna as reverse pharmacognosy. The terms reverse pharmacology or ethnopharmacology serves the same purpose of providing the evidence-based approach to the plant based medicinal systems.
An average BAMS student is least interested in learning dravyaguna skills while pursuing graduation. Probably, lack of pedagogy tools and language barrier can be the possible culprits. However, with the publication and the availability of the quality books, the art of teaching and learning is gradually evolving.
A relevant portion of pharmacology is included in the undergraduate syllabus of dravyaguna. As an observation, it can be argued that the majority of the Ayurveda professionals are inclined towards pharmacology rather than the medicinal herbs.
The Genesis of retaining pharmacology and omitting phytochemistry by NCISM from the latest syllabus is beyond imagination. An integration of dravyaguna with pharmacology and phytochemistry can yield better results for enhancing practical accountability.
このストーリーは、Chronicle Pharmabiz の November 13, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Chronicle Pharmabiz からのその他のストーリー
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
